Evidence map›Paper›PMID 39098116›Full record

ArticleThe Journal of surgical research2024

Center and Individual Willingness to Consider Heart and Lung Offers From Donors With Hepatitis C.

Jessica M Ruck, Mary G Bowring, Laura B Zeiser, Christine M Durand, Allan B Massie, Dorry L Segev, Ahmet Kilic, Elizabeth A King, Errol L Bush

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of surgical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jessica M RuckDivision of Thoracic Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Mary G BowringDivision of Thoracic Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Laura B ZeiserDivision of Transplant Surgery, Department of Surgery, New York University Grossman School of Medicine and Langone Health, New York, New York.
Christine M DurandDivision of Infectious Disease, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Allan B MassieDivision of Transplant Surgery, Department of Surgery, New York University Grossman School of Medicine and Langone Health, New York, New York; Division of Epidemiology, Department of Population Health, New York University Grossman School of Medicine and Langone Health, New York, New York.
Dorry L SegevDivision of Transplant Surgery, Department of Surgery, New York University Grossman School of Medicine and Langone Health, New York, New York; Division of Epidemiology, Department of Population Health, New York University Grossman School of Medicine and Langone Health, New York, New York; Scientific Registry of Transplant Recipients, Minneapolis, Minnesota.
Ahmet KilicDivision of Cardiac Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Elizabeth A KingDivision of Transplant Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Errol L BushDivision of Thoracic Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: errol.bush@jhu.edu.

Funding

Medical Scientist Training ProgramT32GM136577 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ANDREA L COX · 2020 to 2026
$13.4M
A Randomized Controlled Trial of Prophylaxis with Direct-acting Antivirals for Kidney Transplantation from Hepatitis C virus-infected donor to Uninfected Recipients (PREVENT-HCV)U01AI157931 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Christine Marie Durand, DORRY L. SEGEV · 2022 to 2026
$6.1M
Continuous allocation score design for guaranteeing equity and reducing discards in kidney and liver transplantationR01DK132395 · NIDDK · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Allan B Massie · 2023 to 2026
$2.7M
Patient Oriented Research in Kidney Disease and Transplant SurgeryK24DK101828 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI SEGEV, DORRY L. · 2014 to 2018
$922k
Exploring factors influencing gender disparities in access to transplantationR21AG034523 · NIA · JOHNS HOPKINS UNIVERSITY · PI SEGEV, DORRY L. · 2010 to 2011
$502k
Frailty and post-liver transplant delirium and cognitive impairment in older recipientsF32AG067642 · NIA · JOHNS HOPKINS UNIVERSITY · PI RUCK, JESSICA MOORE · 2021 to 2023
$258k
Geriatric-Specific Risks and Outcomes in Older Kidney Tranplant RecipientsF32AG044994 · NIA · JOHNS HOPKINS UNIVERSITY · PI KING, ELIZABETH ANN · 2013 to 2015
$210k
Leveraging a novel health records platform to predict the development of cardiovascular disease following kidney transplantationF30HL168842 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BOWRING, MARY GRACE · 2023 to 2025
$170k
NHLBI NIH HHS F30 HL168842NIAID NIH HHS U01 AI157931NIA NIH HHS F32 AG044994NIA NIH HHS F32 AG067642NIA NIH HHS R21 AG034523NIDDK NIH HHS K24 DK101828NIDDK NIH HHS R01 DK132395NIGMS NIH HHS T32 GM136577
6 · The paper itself

Abstract

introductionTransplants with hearts and lungs from donors with hepatitis C virus (HCV D+) have been proven safe and effective since development of direct-acting antivirals, yet the presence of HCV + persists as a reason to decline organs.

methodsWe identified adult candidates listed January 1, 2015-March 8, 2023 for heart or lung transplant using the Scientific Registry of Transplant Recipients. We identified individual-level and center-level characteristics associated with listing to consider HCV D+ offers using multilevel logistic regression in a multivariable framework.

resultsOver the study period, the annual percentage of candidates willing to consider HCV D+ offers increased for both heart (9.5%-74.3%) and lung (7.8%-59.5%), as did the percentage of centers listing candidates for HCV D+ heart (52.9%-91.1%) and lung (32.8%-82.8%) offers. Candidates at centers with more experience with HCV D+ transplants were more likely to consider HCV D+ organ offers. After adjustment, listing center explained 70% and 78% of the residual variance in willingness to consider HCV D+ hearts and lungs, respectively.

conclusionsAlthough listing for consideration of HCV D+ offers has increased, it varies by transplant center. Center-level barriers to consideration of HCV D+ organs reduce recipients' transplant access.

Indexed as

Heart TransplantationHepatitis CLung TransplantationTissue and Organ ProcurementTissue DonorsAdultAgedFemaleHumansMaleMiddle AgedRegistriesUnited StatesHeart transplantHepatitis CLung transplantOutcomesWaitlist

Identifiers

PMID39098116
PMCPMC11490384

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.